AlphAIAlphAI — Financial news for AI agents
investing.comOCT 62 min read$NEOG

Neogen earnings beat by $0.03, revenue topped estimates

Neogen (NASDAQ: NEOG) reported Q1 EPS of $0.08, beating estimates by $0.03, with revenue of $222.8M, exceeding expectations. The company guided FY 2027 revenue to $885M-$890M. Shares are up 24.32% in 3 months and 113.95% in 12 months, closing at $11.96.

Original reporting
investing.com
Published Oct 6, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$NEOG
Bullish
high confidence
Mentioned
$NEOG
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NEOGBullishHigh
01

Why it matters

The earnings beat and raised guidance may attract momentum traders and institutional buyers focused on high‑growth biotech stocks.

02

Market read

Fresh earnings data provides a clear catalyst for short‑term trading decisions on NEOG.

03

What to watch

Future guidance still below prior expectations; macro‑economic headwinds could temper growth.

Relevance 7/10Novelty 8/10Timing: post‑market today

Background

Neogen is a developer of diagnostic and safety testing solutions for food, animal health, and environmental markets.

Company-level read

Ticker impact

$NEOGBullishHigh confidence
Context

Neogen reported Q1 EPS $0.08, beating the $0.05 estimate by $0.03, and revenue $222.8M versus $204.7M consensus.

Expected impact

potential upside as market prices in the earnings beat and higher guidance

Evidence & confidence

Both EPS and revenue exceeded expectations and guidance was raised, which typically drives buying pressure.

Market effects

Sector

Positive earnings may lift the broader animal health and diagnostics sector.

Regional

U.S. small‑cap biotech/diagnostics segment could see modest gains.

Global

Limited to investors tracking U.S. biotech and diagnostic companies.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face short‑term profit‑taking.

Key entities

  • Company
    Neogen

    NASDAQ‑listed provider of diagnostic and safety testing solutions.

Read at source← All news

Also covered by

2 outlets

Related articles

OCT 6
$NEOGMedAI 8/10

What Neogen (NEOG) Said on Its Q1 Earnings Call

Neogen (NEOG) reported Q1 adjusted EBITDA of $41.6M, up 170 bps YoY. Adjusted net income was $17.5M, EPS $0.08. Free cash flow improved by $18M. Debt stood at $774M, cash at $172M. The company raised fiscal 2027 revenue guidance to $885M-$890M and adjusted EBITDA to $181M-$183M. It expects margin improvements post-Petrifilm transition and announced a collaboration with Hinalea. The genomics sale is under regulatory review, with proceeds earmarked for debt reduction.

finance.yahoo.com2 min
OCT 6
$NEOGMedAI 8/10

Compared to Estimates, Neogen (NEOG) Q1 Earnings: A Look at Key Metrics

Neogen (NEOG) reported Q1 revenues across various segments, generally meeting or exceeding estimates. Food Safety revenues grew 7.3% YoY to $163.2M, while Animal Safety revenues increased 4.3% YoY to $59.6M. Some segments saw significant changes, such as Animal Safety Genomics Services, up 211.4% YoY, and Food Safety Genomics Services, down 59.6% YoY.

finance.yahoo.com2 min
OCT 6
$NEOGMed

Neogen’s (NASDAQ:NEOG) Q3 CY2026: Strong Sales, Stock Soars

Neogen (NEOG) reported Q3 CY2026 revenue of $222.8M, beating estimates by 7% and growing 6.5% YoY. Adjusted EPS of $0.08 beat estimates by 50%. The company raised full-year revenue guidance to $887.5M and EBITDA guidance to $182M, both above analyst estimates. Operating margin improved to -0.8% from -7.7% YoY, and free cash flow turned positive at $4.7M.

finance.yahoo.com2 min
OCT 6
$PENGHighAI 8/10

After-Hours Movers: PENG, STZ, NEOG

Penguin Solutions (PENG) rose 3% after reporting strong Q4 results and upbeat FY2027 guidance. Constellation Brands (STZ) fell 5% despite Q2 beat, citing lower FY2027 EPS guidance. Neogen (NEOG) surged 8% on Q1 beat and raised FY2027 revenue outlook. PENG: $1.00 adj. EPS, $567M revenue; STZ: $3.74 EPS, $2.63B revenue; NEOG: $0.08 EPS, $222.8M revenue.

investing.com2 min
OCT 6
$NEOGHighAI 8/10

Neogen: Fiscal Q1 Earnings Snapshot

Neogen Corp. (NEOG) reported a fiscal Q1 loss of $11.9 million, or 5 cents per share, but adjusted earnings of 8 cents per share, beating analyst estimates. Revenue was $222.8 million, exceeding expectations. The company forecasts full-year revenue between $885M and $890M.

finance.yahoo.com2 min